Most patients with BMI 40 will likely choose retatrutide for its superior results, while those with BMI 30-40 may prefer CagriSema's faster availability
REDEFINE 1 evaluated the combination in adults with overweight or obesity without type 2 diabetes over a 68-week design, comparing the combination against the individual components and placebo [5]
Room temperature (lyophilized): Stable for several weeks when sealed and protected from light
In laboratory settings, it has been studied for its ability to influence growth hormone release patterns , IGF-1 signaling , and pituitary gland response
the two are blurred on labels routinely. Confirm what sequence is in the vial by reviewing third-party lab reports
Some patients may experience: Mild injection site reactions (redness, slight swelling) Temporary drowsiness (related to increased melatonin production) Mild headache in the first few days Serious adverse effects are rare in published literature